Alzheimer Disease documents

Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case-control and cohort study.

Background Neuropathological, animal, and cell culture studies point to a role for the body's own endogenous cannabinoids (eCBs) system in Alzheimer's disease (AD) pathology and treatment. To date, no published studies have investigated the potential utility of circulating eCBs as diagnostic biomarkers for AD or the impact of central eCBs on cognition. Results In comparison with healthy controls, there were no sig…